<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291145</url>
  </required_header>
  <id_info>
    <org_study_id>260910000001</org_study_id>
    <nct_id>NCT03291145</nct_id>
  </id_info>
  <brief_title>Exploring Mechanisms and Morphology of QT Interval Prolongation</brief_title>
  <acronym>TriQarr</acronym>
  <official_title>Exploring Mechanisms and Morphology of QT Interval Prolongation - An Inheritable as Well as an Inducible Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The projects will try and optimise the risk stratification for patients with Long QT syndrome&#xD;
      by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics&#xD;
      and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation.&#xD;
      Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics&#xD;
      tested by &quot;Brisk Standing&quot;.&#xD;
&#xD;
      First, patients are tested with known arrhythmic triggers and they are then administered&#xD;
      thier normal dose of beta blockers. Hereafter, &quot;Brisk Standing&quot; test is performed and the&#xD;
      patients are on Spironolactone for seven days. After seven days treatment the &quot;Brisk&#xD;
      Standing&quot; is repeated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the projects is to try and optimise the risk stratification for patients with Long&#xD;
      QT syndrome by investigating how the exposure of physical and acoustic stress will affect the&#xD;
      QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic&#xD;
      QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on&#xD;
      the QT-dynamics tested by &quot;Brisk Standing&quot;.&#xD;
&#xD;
      First, patients are tested with known arrhythmic triggers and they are then administered&#xD;
      thier normal dose of beta blockers. Hereafter, &quot;Brisk Standing&quot; test is performed and the&#xD;
      patients are on Spironolactone for seven days. After seven days treatment the &quot;Brisk&#xD;
      Standing&quot; is repeated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc</measure>
    <time_frame>7 days</time_frame>
    <description>Corrected QT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Long Qt Syndrome 1-2</condition>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>Beta Blockers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With and without Beta Blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With and without Spironolactone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta Blockers</intervention_name>
    <description>With and without Beta Blockers</description>
    <arm_group_label>Beta Blockers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Brisk Standing before and after seven days treatment with Spironolactone</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified Long QT syndrome mutation, subtype 1 or 2.&#xD;
&#xD;
          -  over 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrioventricular block,&#xD;
&#xD;
          -  Left bundle branch block,&#xD;
&#xD;
          -  Left ventricular hypertrophy,&#xD;
&#xD;
          -  Pace rhythm,&#xD;
&#xD;
          -  ST-deviations &gt;1 mm),&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;50 % and significant valvulopathy,&#xD;
&#xD;
          -  Unstable psychiatric disease&#xD;
&#xD;
          -  Unstable cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herlev-Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Copenhagen</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Peter Marstrand</investigator_full_name>
    <investigator_title>Medical Doctor, Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Long QT Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Romano-Ward Syndrome</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

